- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed since 2014 (GARDASIL 9).
- Why 4/10
- GARDASIL 9 is already approved and commercially marketed with no pending PDUFA, AdComm, or pivotal readout in the next ~12 months. The next hard catalyst would be the confirmatory trial readout for the oropharyngeal cancer indication, but no specific date has been announced. As an approved product at a large diversified pharma company, the binary-catalyst-driven share-price move potential for this single drug is limited.
Watch for the confirmatory trial readout for the oropharyngeal/head-and-neck cancer indication (no date announced), which could convert the accelerated approval to full approval or, in a negative scenario, narrow the label. Also monitor quarterly Gardasil sales trends for evidence of a China demand recovery or further deterioration, and the progress of Merck's single-dose regimen trials, which could expand the addressable market if successful.
Price Chart
Executive Summary
GARDASIL / GARDASIL 9 is Merck's blockbuster HPV vaccine, approved since 2014 and the dominant product in its category. It generated $5.2 billion in 2025 sales (down 39% from 2024) as demand collapsed in China, Merck's largest market for the vaccine. The company halted China shipments in early 2026 and withdrew its $11 billion peak-sales target. Q3 2026 sales of $1.995 billion beat analyst expectations, suggesting some stabilization. A multi-year product-liability MDL is effectively resolved after Merck won summary judgment and settled ~200 remaining cases for ~$50 million in June 2026. The drug faces no imminent binary regulatory catalyst, making it a steady commercial contributor to Merck rather than a near-term share-price swing driver.
How It Works
GARDASIL 9 is a vaccine that trains the immune system to recognize and fight nine strains of human papillomavirus (HPV), a sexually transmitted virus that causes virtually all cervical cancers and a large share of oropharyngeal, anal, vulvar, vaginal, and penile cancers. It contains non-infectious virus-like particles that trigger antibody production without causing infection.
Trial Status
GARDASIL 9 was initially FDA-approved in 2014 and has since received expanded indications including oropharyngeal and head-and-neck cancer prevention (accelerated approval). Merck presented 14- and 18-year follow-up data at the EUROGIN 2026 congress confirming long-term efficacy. A post-marketing confirmatory trial for the oropharyngeal cancer indication is ongoing. Merck has also announced plans for two Phase 3 trials evaluating a single-dose regimen of GARDASIL 9.
The Two-Sided Case
Upcoming Catalysts
- Ongoing confirmatory trial for oropharyngeal/head-and-neck cancer accelerated approval (no specific readout date announced)
- Single-dose regimen Phase 3 trials (enrollment expected to begin; no specific readout date)
- Quarterly sales updates as part of Merck earnings (next: Q4 2026 / full-year 2026, early Feb 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report